Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clopamide is an oral thiazide-like diuretic and antihypertensive agent. Structurally a piperidine and sulfamoylbenzamide-based compound, it acts similarly to thiazide diuretics but lacks the typical double-ring structure. Its primary mechanism of action is inhibition of the sodium-chloride symporter in the distal convoluted tubule (DCT) of the nephron in the kidney. This leads to reduced reabsorption of sodium and chloride ions, resulting in increased excretion of these electrolytes along with water. The drug is used mainly for treating hypertension (high blood pressure) and edema associated with conditions such as congestive heart failure, liver cirrhosis, or renal disorders[1][2][3][4][5][6]. It is administered orally and has a rapid onset (1–2 hours), with effects lasting up to 24 hours[4]. Common side effects include electrolyte imbalances (such as hypokalemia), dizziness, gastrointestinal disturbances, photosensitivity reactions, and others[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clopamide.